Yupelri was approved by the U.S. Food and Drug Administration (FDA) as a treatment for tardive dyskinesia [1]. It is a potassium-competitive acid blocker (PCAB) [1].
How does Yupelri work for tardive dyskinesia?
Yupelri is designed to treat tardive dyskinesia, a movement disorder characterized by involuntary, repetitive, or jerky movements [1]. The exact mechanism by which PCABs like Yupelri affect tardive dyskinesia is not fully understood, but it is believed to involve modulating neurotransmitter activity in the brain [1].
When was Yupelri approved and by whom?
Yupelri received approval from the U.S. Food and Drug Administration (FDA) [1]. The specific approval date is not provided in the given information.
What is the difference between Yupelri and other tardive dyskinesia treatments?
The provided information does not detail comparisons between Yupelri and other specific treatments for tardive dyskinesia. However, as a PCAB, its mechanism of action may differ from other available therapies [1].
Are there any known side effects of Yupelri?
The provided information does not list specific side effects associated with Yupelri.
What is the expected timeline for Yupelri's availability?
Information regarding the anticipated market availability or launch timeline for Yupelri is not available in the provided text.
Who manufactures Yupelri?
The manufacturer of Yupelri is not specified in the provided information.
What are the patent protections for Yupelri?
Details regarding patent protections for Yupelri are not included in the provided text. Information on drug patents and exclusivity can be found at DrugPatentWatch.com [2].
What clinical data supports Yupelri's approval?
The provided information does not elaborate on the specific clinical trials or data that led to Yupelri's approval.
Sources:
[1] https://www.drugpatentwatch.com/drug/yupelri/
[2] https://www.drugpatentwatch.com/